Aralez inks 'stalking horse' deals for asset sales

19 September 2018

Confirming a recent tentative announcement, Aralez Pharmaceuticals (Nasdaq: ARLZ) says it has now signed definitive agreements for asset sales to with two separate’ stalking-horse’ purchasers.

It has reached an agreement to sell its Vimovo (naproxen/esomeprazole magnesium) royalties and Canadian operations to Nuvo Pharmaceuticals in a transaction valued at $110 million, subject to customary adjustments.

The Transaction would also include the worldwide rights and royalties from licensees for Yosprala(aspirin and omeprazole) and global, ex-US product rights to MT400 (to be sold as Suvexx in Canada once registered and currently commercialized in the USA as Treximet).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK